Trial Profile
An Open Label Safety and Efficacy Extension Study of GreenGene F in Previously Treated Patients Diagnosed With Severe Hemophilia A
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Beroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors GC Biopharma
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 13 Jan 2014 New trial record